- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01063036
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
25 de novembro de 2014 atualizado por: Bristol-Myers Squibb
A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure
The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
144
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- Local Institution
-
Berlin, Alemanha, 10969
- Local Institution
-
Hamburg, Alemanha, 20246
- Local Institution
-
Hamburg, Alemanha, 20099
- Local Institution
-
Hannover, Alemanha, 30625
- Local Institution
-
Heindelberg, Alemanha, 69120
- Local Institution
-
Munchen, Alemanha, 81675
- Local Institution
-
Tubingen, Alemanha, 72076
- Local Institution
-
-
-
-
-
Barcelona, Espanha, 08025
- Local Institution
-
Valencia, Espanha, 46014
- Local Institution
-
-
-
-
-
Clichy, França, 92110
- Local Institution
-
Lyons Cedex 04, França, 69317
- Local Institution
-
Orleans Cedex 2, França, 45067
- Local Institution
-
Strasbourg, França, 67000
- Local Institution
-
-
-
-
-
Amsterdam, Holanda, 1105 AZ
- Local Institution
-
Arnhem, Holanda, 6815 AD
- Local Institution
-
Rotterdam, Holanda, 3015 CE
- Local Institution
-
-
-
-
-
Bagno A Ripoli (Fi), Itália, 50012
- Local Institution
-
Bari, Itália, 70124
- Local Institution
-
Foggia, Itália, 71100
- Local Institution
-
Milano, Itália, 20122
- Local Institution
-
-
-
-
-
Kielce, Polônia, 25-317
- Local Institution
-
Krakow, Polônia, 31-531
- Local Institution
-
Lodz, Polônia, 91-347
- Local Institution
-
Wroclaw, Polônia, 50-349
- Local Institution
-
-
-
-
-
Bucuresti, Romênia, 021105
- Local Institution
-
Burcuresti, Romênia, 022328
- Local Institution
-
Timisoara, Romênia, 300 002
- Local Institution
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Subjects with chronic hepatitis B virus (HBV) infection; either hepatitis B-e antigen(HBeAg)-negative or HBeAg-positive
- Subjects must have a treatment failure to their current nucleoside/ nucleotide treatment regimen
- Prior entecavir and/or tenofovir monotherapy is allowed
- Subjects must have compensated liver function
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Evidence of decompensated cirrhosis
- Co-infection with HIV, hepatitis C virus (HCV), or hepatitis D virus (HDV)
- Moderate or severe renal impairment
- Recent history of pancreatitis
- Therapy with interferon, thymosin alpha or other immuno-stimulators within 24 weeks of being assigned to study drug into this study
- Prior entecavir/tenofovir combination therapy
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Entecavir + Tenofovir
|
Tablets, Oral, 1 mg, once daily, 96 weeks
Outros nomes:
Tablets, Oral, 300 mg, once daily, 96 weeks
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With a Virologic Response at Week 48 - Treated Population
Prazo: Week 48
|
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL.
Percentage was calculated as number of participants with virologic response at Week 48 divided by the number of treated participants.
Treated participants were evaluated using non-completer (NC) = failure (F).
The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay, in a central laboratory.
The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL.
HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
|
Week 48
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With a Virologic Response at Week 24 and at Week 96 - Treated Population
Prazo: Week 24, Week 96
|
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL.
Percentage was calculated as number of participants with virologic response at Week 24, Week 96 divided by the number of treated participants.
Treated participants were evaluated using non-completer (NC) = failure (F).
The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay.
The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL.
HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
|
Week 24, Week 96
|
Change From Baseline in Mean log10 HBV DNA at Weeks 12, 24, 48, and 96 - Treated Evaluable Population
Prazo: Baseline to Weeks 12, 24, 48, 96
|
HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay.
The results were reported in log 10 IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL.
HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
Baseline was Day 1, prior to study drug administration.
|
Baseline to Weeks 12, 24, 48, 96
|
Percentage of Participants With HBV DNA Less Than the Lower Limit of Detection (LLD) at Weeks 24, 48, and 96 - Treated Population
Prazo: Weeks 24, 48, 96
|
HBV DNA less than (<) LLD (6 IU/mL) was defined/measured by the COBAS(REGISTERED) TaqMan HPS assay at Weeks 24, 48, and 96.
Percentage was calculated as number of participants with HBV DNA < LLD at Weeks 24, 48, 96 divided by the number of treated participants.
Treated participants were evaluated using non-completer (NC) = failure (F).
|
Weeks 24, 48, 96
|
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg Positive at Baseline
Prazo: Baseline to Weeks 24, 48, and 96
|
Loss of HBeAg was defined as being HBeAg-negative at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline.
Method used for HBeAg was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples.
Percentage was calculated as number of participants with HBeAg loss at Weeks 24 and 48 divided by the number of treated participants who were HBeAg-positive at baseline.
Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
|
Baseline to Weeks 24, 48, and 96
|
Percentage of Participants With HBe Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg-positive at Baseline
Prazo: Baseline, Weeks 24, 48, and 96
|
HBe seroconversion was defined as being both HBeAg-negative and HBeAb-positive at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline.
Method used was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples.
Percentage was calculated as number of participants with HBe seroconversion at Weeks 24, 48, and 96 divided by the number of treated participants who were HBeAg-positive at baseline.
Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
|
Baseline, Weeks 24, 48, and 96
|
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 24, 48, 96 - Treated Population Who Were HBsAg-Positive at Baseline
Prazo: Baseline, Weeks 24, 48, 96
|
Loss of HBsAg was defined as being HBsAg-negative at Weeks 24, 48, 96 in those participants who had been HBsAg-positive at baseline.
The method used: Immunoassay - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma (potassium ethylene diamine tetraacetic acid, lithium or sodium heparinized).
Percentage calculated as number of participants with a HBsAg loss at Weeks 24, 48, and 96 divided by the number of treated participants who were HBsAg-positive at baseline (participants were not enrolled into the study unless they were positive for HBsAg).
Treated participants (HBsAg-positive at baseline) were evaluated using NC=F.
Baseline was Day 1, before start of study drug.
|
Baseline, Weeks 24, 48, 96
|
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBsAg-Positive at Baseline
Prazo: Baseline, Weeks 24, 48, and 96
|
HBsAg seroconversion was defined as being both HBsAg-negative and HBsAb-positive at Weeks 24, 48, and 96 in those participants who had been HBsAg-positive at baseline.
Percentage was calculated as number of participants with HBs seroconversion at Weeks 24 and 48 divided by the number of treated participants who were HBsAg-positive at baseline.
Positive result for HBsAg was one of the inclusion criteria.
Treated participants (HBsAg positive at baseline) were evaluated using NC=F.
The method used was an Immunoassay testing - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma [potassium ethylenediaminetetraacetic acid (EDTA), lithium or sodium heparinized].
Baseline was Day 1, before start of study drug.
|
Baseline, Weeks 24, 48, and 96
|
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) on Treatment, and Discontinuation of Study Drug Due to Adverse Events (AE) - Treated Population
Prazo: Day 1 to last dose of study drug plus 5 days; up to Week 96
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
On-treatment = on Day 1 through last dose of study therapy + 5 days.
|
Day 1 to last dose of study drug plus 5 days; up to Week 96
|
Number of Participants With Emergence of Genotypic Resistance to Study Drugs at Weeks 48 and 96- Treated Population
Prazo: Baseline to Weeks 48, 96
|
Testing of HBV genotype was performed at baseline for all treated patients and for participants at Weeks 48 and 96 with primary non-response or virologic breakthrough.
Emergent genotypic resistance to study drugs was defined as follows: Emergent = not detected at baseline; entecavir (ETV) resistance (ETVr): participant's sample was to have rtM204V/I/S and any substitution at rtT184, rtS202, or rtM250; tenofovir (TDF) resistance (TDFr) which was based on adefovir (ADV)-mutations: participant's sample was to have rtA181T/V, rtN236T, or (rtA194T and rtM204V/I/S).
Primary non-response was defined as < 1 log10 decrease in HBV DNA from baseline on treatment at or after Week 12. Virologic breakthrough was defined as ≥ 1 log10 increase in HBV DNA over nadir on treatment, either confirmed or last on-treatment followed by discontinuation of study therapy.
|
Baseline to Weeks 48, 96
|
Number of Participants on Treatment With Study Drug With Laboratory Test Abnormalities Meeting Selected Criteria on Treatment - Treated Population
Prazo: Day 1 to last dose of study drug plus 5 days; up to Week 96
|
Selected criteria presented in each category.
Upper limit of normal among all laboratory ranges (ULN); Baseline (BL); alanine transaminase (ALT); milligram per deciliter (mg/dL); milliliters per minute (mL/min); greater than (>);greater than, equal to (>=); less than (<).
Creatinine data presented below were confirmed, ie, at least 2 consecutive values.
On-treatment = after Day 1 through last dose of study therapy + 5 days.
|
Day 1 to last dose of study drug plus 5 days; up to Week 96
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Links úteis
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de maio de 2010
Conclusão Primária (Real)
1 de novembro de 2012
Conclusão do estudo (Real)
1 de fevereiro de 2014
Datas de inscrição no estudo
Enviado pela primeira vez
3 de fevereiro de 2010
Enviado pela primeira vez que atendeu aos critérios de CQ
4 de fevereiro de 2010
Primeira postagem (Estimativa)
5 de fevereiro de 2010
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
15 de dezembro de 2014
Última atualização enviada que atendeu aos critérios de controle de qualidade
25 de novembro de 2014
Última verificação
1 de novembro de 2014
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças do Fígado
- Hepatite, Viral, Humana
- Infecções Hepadnaviridae
- Infecções por vírus de DNA
- Infecções por Enterovírus
- Infecções por Picornaviridae
- Hepatite B
- Hepatite
- Hepatite A
- Hepatite B Crônica
- Hepatite Crônica
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores da transcriptase reversa
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Tenofovir
- Entecavir
Outros números de identificação do estudo
- AI463-203
- 2009-015705-40 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Hepatite B crônica
-
Lapo AlinariRecrutamentoTegavivint para o tratamento de pacientes com linfoma de grandes células B recidivante ou refratárioLinfoma recorrente de células B de alto grau com rearranjos MYC, BCL2 e BCL6 | Linfoma de células B de alto grau refratário com rearranjos MYC, BCL2 e BCL6 | Linfoma recorrente de células B de alto grau com rearranjos MYC e BCL2 ou BCL6 | Linfoma de células B de alto grau refratário com... e outras condiçõesEstados Unidos
-
Nathan DenlingerBristol-Myers SquibbRecrutamentoLinfoma Não-Hodgkin de Células B Recorrente | Linfoma difuso de grandes células B recorrente | Linfoma Folicular Recorrente | Linfoma de células B de alto grau recorrente | Linfoma primário mediastinal de grandes células B recorrente | Linfoma não-Hodgkin indolente de células B transformado em... e outras condiçõesEstados Unidos
-
National Cancer Institute (NCI)Ativo, não recrutandoLinfoma Difuso Recorrente de Grandes Células B Ativado Tipo de Células B | Linfoma Difuso Refratário de Grandes Células B Ativado Tipo de Células BEstados Unidos, Arábia Saudita
-
Ohio State University Comprehensive Cancer CenterRecrutamentoLinfoma Difuso de Grandes Células B | Linfoma de Células B de Alto Grau | Linfoma Difuso de Grandes Células B, Sem Outra Especificação | Linfoma Difuso de Grandes Células B Centro Germinal Tipo de Células BEstados Unidos
-
Athenex, Inc.RecrutamentoLinfoma de células B | CLL/SLL | TODOS, Infância | DLBCL - Linfoma Difuso de Grandes Células B | Leucemia de células B | NHL, recaída, adulto | ALL, Célula B adultaEstados Unidos
-
Northwestern UniversityNational Cancer Institute (NCI)Ativo, não recrutandoLinfoma Difuso de Grandes Células B | Linfoma Difuso de Grandes Células B, Sem Outra Especificação | Linfoma de Células B de Alto Grau, Sem Outra Especificação | Linfoma de Células B Grandes Rico em Histiócitos/Células T | Linfoma de células B de alto grau com rearranjos MYC e BCL2 e/ou BCL6 | Linfoma Difuso de Grandes Células B Ativado Tipo de Células... e outras condiçõesEstados Unidos
-
M.D. Anderson Cancer CenterRecrutamentoLinfoma Difuso Recorrente de Grandes Células B | Linfoma de Células B Grandes do Mediastino Primário Recorrente (Tímico) | Linfoma difuso de grandes células B refratário | Linfoma de Células B Grandes do Mediastino Primário (Tímico) Refratário | Linfoma não Hodgkin agressivo recorrente de... e outras condiçõesEstados Unidos
-
National Cancer Institute (NCI)RecrutamentoLinfoma de Células B de Alto Grau | Linfoma Difuso de Grandes Células B, Sem Outra Especificação | Linfoma não Hodgkin indolente transformado de células B em linfoma difuso de grandes células BEstados Unidos
-
Northwestern UniversityNational Cancer Institute (NCI)RecrutamentoLinfoma de Células B Grandes do Mediastino Primário Recorrente (Tímico) | Linfoma de Células B Grandes do Mediastino Primário (Tímico) Refratário | Linfoma recorrente de células B de alto grau com rearranjos MYC, BCL2 e BCL6 | Linfoma de células B de alto grau refratário com rearranjos... e outras condiçõesEstados Unidos
-
ImmunoVaccine Technologies, Inc. (IMV Inc.)Merck Sharp & Dohme LLCRecrutamentoLinfoma Difuso de Grandes Células B Recidivante | Linfoma Difuso de Grandes Células B RefratárioAustrália, Espanha, Estados Unidos, França, Hungria, Nova Zelândia, Polônia, Sérvia, Canadá, Romênia
Ensaios clínicos em Entecavir
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... e outros colaboradoresDesconhecidoCirrose Hepática Devido ao Vírus da Hepatite BChina
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People's... e outros colaboradoresConcluído
-
Sunshine Lake Pharma Co., Ltd.Suspenso
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... e outros colaboradoresDesconhecido
-
Taipei Veterans General Hospital, TaiwanBristol-Myers SquibbConcluídoHepatite B | Linfoma não-HodgkinTaiwan
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People's... e outros colaboradoresConcluído
-
National Taiwan University HospitalDesconhecidoCoinfecção VHB/VHCTaiwan
-
Taipei Veterans General Hospital, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Changhua Christian...DesconhecidoHepatite B crônica
-
Peking UniversityDesconhecido
-
Sun Yat-sen UniversityDesconhecidoNeoplasias ColorretaisChina